At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Twice a Day Clopidogrel vs Ticagrelor in Reducing Major Cardiac Events in Patients With Acute STEMI Undergoing Primary Percutaneous Intervention- TADCLOT- a Double Blind Randomized Controlled Trial
In Brief
A Phase 3 clinical trial evaluating Ticagrelor 90 MG and Clopidogrel for Stent Thrombosis and Myocardial Infarction, Acute. Completed, enrolled 2,200 participants across 1 site.
Detailed Summary
Compare the safety and efficacy of a twice-daily Clopidogrel regimen vs. Ticagrelor in reducing major adverse events in patients undergoing primary PCI in a double-blind randomized controlled trial.
Study Details
Timeline
Interventions
Patients in the treatment group will receive Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose for 30 days. After 30-day doses will be according to standards clinical practice guidelines.
Patients in the control group will receive Clopidogrel 600 mg as a loading dose and 75 mg twice daily as a maintenance dose for 30 days. After 30-day doses will be according to standards clinical practice guidelines.